Introduction:
With advancements in technology, people with diabetes now have access to closed-loop insulin delivery systems, also known as “bionic pancreases”. These systems use a continuous automatically ous glucose monitor (CGM) and an insulin pump connected to a control algorithm to adjust insulin delivery based on real-time glucose levels, providing a more accurate and responsive approach to insulin therapy.
How Closed-Loop Insulin Systems Make Diabetes Easier to Manage
Closed-loop insulin delivery systems use a continuous glucose monitor (CGM) to continuously track a person’s blood sugar levels. This information is then fed into an algorithm that automatically adjusts the insulin delivery from an insulin pump to match the person’s needs.
This allows the system to closely mimic the natural insulin-secreting function of a healthy pancreas. By automatically adjusting insulin delivery in real-time based on actual glucose levels, these systems can help people with diabetes achieve better blood sugar control, reduce the risk of hypoglycemia (low blood sugar), and improve their long-term HbA1c levels.
The key benefit is that the closed-loop system can respond to changes in glucose levels much more quickly and accurately than a person manually adjusting their insulin. This takes a lot of the burden of diabetes management off the patient, especially for children and older adults who may have difficulty closely monitoring their blood sugar.
Hybrid Closed-Loop Insulin Systems: Development and Benefits
While closed-loop insulin delivery systems are still in development, several companies and research groups have made significant progress in their development. Currently, the systems available are called hybrid closed loop systems. They still require work from the user, but offer a way of managing diabetes that can improve blood glucose levels.
GluCare Health’s Partnership for Closed-Loop Insulin Systems
As healthcare professionals at GluCare Health, we are excited about the potential of closed-loop insulin delivery systems and are partnering with Insulet (makers of Omnipod insulin pump) and Dexcom to launch closed-loop insulin delivery systems soon. However, it’s important to note that these systems are not yet widely available and should only be used under the guidance of a healthcare professional.
In conclusion, closed-loop insulin delivery systems have the potential to revolutionize diabetes care and improve the lives of millions of people with diabetes. If you are interested in this type of therapy, speak with your healthcare provider to understand if it is an option for you.
